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Abstract
The extent to which polyfluoroalkyl compounds (PFCs) are detectable in amniotic fluid is
unknown. Using paired samples from 28 women, we compared the concentration of 8 PFCs
measured in serum, the standard matrix for assessing human exposure, amniotic fluid from routine
amniocentesis, and urine. Perfluorooctanoate (PFOA), perfluorononanoate (PFNA),
perfluorooctane sulfonate (PFOS), and perfluorohexane sulfonate (PFHxS) were detected in all
maternal serum samples. The number of amniotic fluid samples with detectable concentrations
differed by PFC (PFOA n=24; PFNA n=10; PFOS n=9; PFHxS n=4). The correlation coefficient
between maternal serum and amniotic PFC levels varied considerably by PFC (PFOA ρ=0.64,
p<0.001; PFNA ρ=0.05, p=0.9; PFOS ρ=0.76, p=0.01; PFHxS ρ=0.80, p=0.2). Using linear
regression, PFOA appeared to be commonly detected in amniotic fluid if the serum concentration
exceeded approximately 1.5 ng/mL whereas PFOS was rarely detected in amniotic fluid until the
serum concentration was about 5.5 ng/mL. No PFCs were detected in urine.
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1. Introduction
Perfluorooctanoate (PFOA) is a synthetic chemical that has been used in the manufacture of
fluoropolymers since the 1950s [1], and may also result from the breakdown of a related
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group of chemicals called fluorinated telomers (alcohols and related compounds) [2].
Fluoropolymers are used in almost all industry segments, including aerospace; automotive;
building/construction; chemical processing; electrical and electronics; semiconductor; and
textile [2]. Telomers are used as surfactants and as surface treatment chemicals in many
products, including firefighting foams; personal care and cleaning products; and oil, stain,
grease, and water repellent coatings on carpet, textiles, leather, and paper [2]. Human
exposure to PFCs typically occurs through transfer from food packaging and preparation
materials and bioaccumulation in the food chain, as well as exposure to household dust [3].
PFOA and other polyfluoroalkyl compounds (PFCs) with comparable industrial uses –
perfluorooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), perfluorononanoate
(PFNA) – are persistent organic pollutants that have been detected worldwide in both
wildlife and humans, with higher exposure closer to urbanized and industrialized regions
[4]. In the United States (U.S.) general population, PFOA, PFOS, and PFHxS were detected
in the serum of all participants from the 1999 – 2000 National Health and Nutrition
Examination Survey (NHANES); PFNA was detected in 95% of participants [5]. In
NHANES 2003 – 2004, there were minor reductions in the percent of samples with
detectable concentrations of PFOA, PFOS, and PFHxS, and the geometric mean
concentrations for these three compounds dropped slightly [6]. For PFNA, however, in
addition to an increase in the percent of serum samples with detectable concentrations to
98.8%, the geometric mean doubled to 1.0 ng/mL between NHANES cycles. In the 2005 –
2006 and 2007 – 2008 NHANES surveys, the percent of samples with detectable
concentrations of these chemicals remained stable, although the concentrations increased
slightly for all but PFOS [7]. In the 2007 – 2008 NHANES, the geometric mean (95%
confidence interval (CI)) concentration of these chemicals in females aged 12 years or older
was 3.56 ng/mL (3.38–3.74) for PFOA; 10.70 ng/mL (9.72–11.8) for PFOS; 1.46 ng/mL
(1.30–1.64) for PFHxS; and 1.33 ng/mL (1.20–1.47) for PFNA [7]. The serum elimination
half-life is estimated at 2.3 [8] to 4 [9] years for PFOA, 5 years for PFOS [9], and 8.5 years
for PFHxS [9]. A half-life estimate is not available for PFNA.
Toxicology studies highlight the potential for PFCs to affect fetal growth and development
(reviewed in [10–12]). Rat pups prenatally exposed to PFOS show delayed behavioral
milestones [13], and delayed task learning has been noted in female mouse pups prenatally
exposed to PFOS and maternal restraint [14]. The limited developmental toxicology
literature suggests possible adverse effects of PFOA and PFOS on fetal growth and viability
and postnatal growth [11, 15].
Several epidemiologic studies have evaluated the association between PFCs and
reproductive health [16–19]. These recently reviewed studies suggest small, inconsistent
decrements in birth weight in relation to maternal PFOA and PFOS exposure [12]. No
associations have been observed with gestational age, examined either continuously [16, 20]
or dichotomized as birth less than 37 completed weeks gestation [17, 20]. Studies of other
indications of fetal growth, such as head and abdominal circumference, birth length, and
ponderal index, have yielded equivocal results [16, 18, 19]. Among a subset of women
exposed to higher than background levels of PFOA through contaminated drinking water but
typical levels of PFOS, there were modest associations of PFOA with preeclampsia [21, 22]
and of PFOS with preeclampsia and low birthweight [22].
PFOA and PFOS have been detected in amniotic fluid from mouse and rat models [23, 24].
In humans, PFCs have been detected in matched maternal prenatal blood, umbilical cord
blood, breast milk, and infant blood samples [25–30]. Several PFCs have been detected
across all matrices. The maternal:cord blood as well as the maternal blood:breast milk
transfer ratios are greater for PFOA than for PFOS. A recent study describes the detection of
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PFOS in 300 stored human amniotic fluid samples from amniocenteses occurring in 1980 to
1996 [31]. We tested amniotic fluid for PFCs, and compared the concentrations measured in
paired maternal serum and amniotic fluid samples. We also tested maternal urine for PFCs,
although urine is rarely used for PFC biomonitoring in humans.
2. Materials and Methods
The Study of Advanced Reproductive Age and Environmental Health (SARAEH) was a
prospective pregnancy cohort designed to assess toxicant exposures among women
undergoing amniocentesis for an indication of advanced maternal age. SARAEH enrolled 97
pregnant women from 2005 – 2008 who were receiving amniocentesis and planning to
deliver at the Mount Sinai Medical Center in New York, NY. Amniotic fluid supernatant
that would normally have been discarded after completion of clinical care investigations was
retained for this study. Spot urine samples were collected from women on the same day as
their amniocentesis appointment and were immediately aliquoted and stored at −80°C.
Peripheral blood samples were collected during routine prenatal care venipuncture, although
blood samples were available only for 42 women (43%). Blood samples were generally
collected at prenatal care visits several weeks after amniotic fluid and urine collection. There
were no statistically significant differences in maternal demographics (maternal age, race/
ethnicity, marital status, education) or pregnancy characteristics (gestational age at
enrollment, parity, pre-pregnancy body mass index (BMI), pregnancy weight gain) between
the women with and without blood samples. From this group of 42 women with both
amniotic fluid and serum samples, we randomly selected 28 (67%) for study inclusion.
Fresh amniotic fluid was delivered to the Mount Sinai Human Medical Genetics laboratory
for processing following collection for clinical analyses. Amniotic fluid was centrifuged and
cells were separated for clinical care purposes, along with a small amount of supernatant.
Residual amniotic fluid supernatant was stored in plastic containers at −20°C for one month
before being released for research purposes. Once released for research, amniotic fluid was
obtained by study personnel and aliquoted into 2 mL polypropylene cyrovials for storage at
−80°C. Paired amniotic fluid, serum, and urine samples collected from the same woman
were shipped to the U.S. Centers for Disease Control and Prevention (CDC) for laboratory
analysis. Institutional Review Board approval for this study was granted from the Mount
Sinai Program for the Protection of Human Subjects. The involvement of the CDC
laboratory was determined not to constitute engagement in human subject research.
We measured perfluorooctane sulfonamide (PFOSA), 2-(N-ethyl-perfluorooctane
sulfonamido) acetate (Et-PFOSA-AcOH), 2-(N-methyl-perfluorooctane sulfonamido)
acetate (Me-PFOSA-AcOH), PFHxS, PFOS, PFOA, PFNA, and perfluorodecanoate
(PFDeA) in serum, urine, and amniotic fluid using a modification of the online solid-phase
extraction (SPE) coupled to reversed-phase high-performance liquid chromatography–
tandem mass spectrometry approach previously described [32]. We used 13C2-PFOA, 18O2-
PFOS, 18O2-PFOSA,13C5-PFNA, 13C2-PFDeA, D3-Me-PFOSA-AcOH, D5-Et-PFOSA-
AcOH and 18O2-PFHxS as internal standards. Limits of detection (LODs), calculated as 3S0,
where S0 is the standard deviation as the concentration approaches zero, ranged from 0.1 ng/
mL to 0.2 ng/mL. Low-concentration (~2 ng/mL – ~10 ng/mL) and high-concentration (~5
ng/mL– ~25 ng/mL) quality-control (QC) materials were analyzed with blanks, analytical
standards and study samples. The QC concentrations were evaluated using standard
statistical probability rules.
Statistical analysis was performed using SAS version 9.2 (Cary, NC) and Stata version 10
(College Station, TX). We examined the relation between PFC concentrations measured in
paired maternal serum and amniotic fluid samples using the Spearman correlation
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coefficient. Correlation coefficients were calculated only among the samples where the
concentration was above the LOD for both amniotic fluid and serum. We also used graphical
techniques to visualize the paired concentration distributions. In some graphical depictions
concentrations below the LOD were plotted at the LOD divided by the square root of 2.
Lastly, we used independent group T-tests to examine whether detection of PFCs in
amniotic fluid varied by maternal age at amniocentesis, gestational age at amniocentesis, or
pre-pregnancy body mass index (BMI).
3. Results
Women were enrolled in their second trimester (mean 17.4 weeks; standard deviation (SD)
2.0; range 15 – 23) at a mean maternal age of 34.8 (SD 5.1) years (Table 1). On average 6.8
(SD 5.5) weeks elapsed between collection of amniotic fluid and serum samples. The
majority of women (53.8%) were pregnant for at least the third time.
Six of eight PFCs tested were detected in maternal prenatal serum, five of eight PFCs tested
were detected in amniotic fluid, and no PFCs tested were detected in maternal prenatal urine
(Table 2). We detected PFHxS, PFOS, PFOA, and PFNA in all of the serum samples; two
other PFCs were detected less frequently (Me-PFOSA-AcOH, 64% and PFDeA, 89%). We
did not detect PFOSA or Et-PFOSA-AcOH in any of the serum or amniotic fluid samples.
Detection of PFCs in amniotic fluid did not vary by parity or pre-pregnancy BMI (data not
shown). Detection did vary by maternal age (p=0.03) and gestational age (p<0.001) for
PFOA only. Both the concentrations and the frequency of detection of all PFCs in amniotic
fluid were lower than in serum. The median concentrations in amniotic fluid were around
the limit of quantification (3*LOD) of the analytical method. The Spearman correlation
coefficient, a measure of rank order used to compare the paired serum and amniotic fluid
concentrations, varied considerably by PFC (PFOA ρ=0.64, p<0.001; PFNA ρ=0.05, p=0.9;
PFOS ρ=0.76, p=0.01; PFHxS ρ=0.80, p=0.2). The sulfonates (PFHxS and PFOS), although
detected less frequently in amniotic fluid than the carboxylates (PFOA and PFNA), showed
stronger correlations between serum and amniotic fluid. The medians of the ratios of
maternal serum:amniotic fluid concentrations were 12.8:1 for PFOA and 25.5:1 for PFOS.
Based on simple regression (Figures 1A, 1B), PFOA was commonly detected in amniotic
fluid once the serum concentration reached approximately 1.5 ng/mL, whereas PFOS was
rarely detected in amniotic fluid until the serum concentration reached at least 5.5 ng/mL.
4. Discussion
We detected PFCs in amniotic fluid at concentrations approximately 10 to 20-fold lower
than in maternal serum. We did not detect PFCs in urine. Maternal prenatal serum
concentrations in this small number of New York City pregnant women are comparable to
national averages from NHANES 2005 – 2006 and 2007 – 2008. In our study, the highest
PFC concentrations in serum were PFOA and PFOS, and these compounds were among the
most frequently detected PFCs in amniotic fluid.
Amniotic fluid concentrations of the PFCs we detected were lower than those reported by
Jensen et al [31] and considerably lower than cord blood concentrations noted in previous
studies [25–30]. In general, maternal blood concentrations are about 1 to 2-fold higher than
paired cord blood concentrations, and maternal:cord blood ratios are lower for PFOA
(~1.3:1) than PFOS (~3.0:1) [33]. The maternal serum:amniotic fluid ratios we observed
replicated this doubled proportionality between the PFOA and PFOS materal:cord blood
ratios. A lower maternal:cord blood ratio indicates that PFOA is more readily transferred to
the fetus than PFOS. Consequently, the fetus may have a greater body burden of PFOA that
can be partitioned into amniotic fluid from fetal tissue. Alternatively, we may have detected
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PFOA in amniotic fluid more frequently than PFOS because the limit of detection for PFOS
was twice as high.
Amniotic fluid is an aqueous solution with suspended desquamated fetal epithelial cells [34].
As gestation progresses, other organic material including fetal feces and urine are also
present. The fluid contains approximately equal parts organics (proteins, carbohydrates, fats,
enzymes, hormones, pigments) and inorganics. In human sera, PFCs associate with
circulating proteins [35]. It is possible that some PFCs were removed from the amniotic
fluid during its initial processing for clinical care purposes when the fluid was centrifuged
and the precipitated cells retained for genetic testing. If the individual PFCs have differential
protein binding preferences, they may have been differentially removed from the fluid
supernatant available for this investigation. This potential reduction in PFC concentration
would have limited our ability to detect the compounds as well as impacting the
concentrations we measured.
In the amniotic fluid samples in this study, PFOA appeared to be more soluble than PFOS
because it was detected in amniotic fluid at lower maternal serum levels than PFOS (Figures
1A, 1B). These findings are consistent with the relative solubility of PFCs in water (PFOA:
3400 mg/L; PFOS: 570 mg/L). Solubility may also partially explain the lower PFOA
maternal:cord blood ratio because cord serum is more polar than maternal serum [36]. In
addition to differential solubility, protein binding across matrices, carbon chain length, and
the charged functional moiety of the compound, such as the carboxylate in PFOA and PFNA
compared with the sulfonate in PFOS and PFHxS, may account for some of the variation in
concentrations of PFCs we observed in amniotic fluid [37].
Based on this and other studies, the relative concentrations of PFOA and PFOS in maternal
serum, cord serum, amniotic fluid, and urine are approximately 100:50:5:0.1. In a Japanese
study, the ratio of PFOA and PFOS in serum as compared to urine was approximately
1000:1 [38]. This ratio is consistent with the undetectable levels we found in urine because
our LOD ranged from 0.1 – 0.2 ng/mL as compared to the 0.001 ng/mL reported in the
Japanese study.
While we cannot rule out the possibility of external contamination because the amniotic
fluid samples had been processed previously, the detection of PFCs in amniotic fluid
suggests that in addition to blood borne in utero exposure [16, 25–30] the fetus is also
ingesting and bathing in low levels of some PFCs.
Several PFCs are persistent organic pollutants under the Stockholm Convention. These
chemicals have long elimination half-lives (e.g., years) and some of them can accumulate
and biomagnify in the food chain. Animal studies show hepatoxicity, developmental
toxicity, immunotoxicity, hormonal effects, and carcinogenic potency. Studies of potential
human health effects are ongoing. The detection of several PFCs in amniotic fluid calls for
replication of these findings, including examination by maternal age, parity, inter-pregnancy
interval, and gestational age at amniotic fluid collection. This study increases the urgency to
identify any potential reproductive and development toxicity of these compounds.
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• Six of eight PFCs tested were detected in maternal prenatal serum; five of eight
PFCs tested were detected in amniotic fluid; no PFCs tested were detected in
maternal prenatal urine
• PFOA was commonly detected in amniotic fluid if the serum concentration
exceeded approximately 1.5 ng/mL
• PFOS was rarely detected in amniotic fluid until the serum concentration was
about 5.5 ng/mL
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Figure 1A. Comparison of PFOA and PFOS concentration measured in paired samples of
maternal prenatal serum and amniotic fluid, New York, NY, 2005 – 2008, n=28. Amniotic
fluid concentrations below the LOD (0.1 ng/mL, PFOA; 0.2 ng/mL, PFOS) were plotted at
the LOD divided by the square root of 2. PFOA=perfluorooctanoate; PFOS=perfluorooctane
sulfonate2
Figure 1B. Comparison of PFOA and PFOS concentration measured in paired samples of
maternal prenatal serum and amniotic fluid, New York, NY, 2005 – 2008, n=28. Amniotic
fluid concentrations below the LOD (0.1 ng/mL, PFOA; 0.2 ng/mL, PFOS) were not plotted.
PFOA=perfluorooctanoate; PFOS=perfluorooctane sulfonate 1.5
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Table 1
Pregnancy Cohort Characteristics, New York, NY, 2005 – 2008, n=28
Maternal Characteristics N (mean) Percent (SD)
Maternal age at enrollment, years 33.9 5.5
Gestational age at enrollment, weeks 17.6 2.3
Time from amniotic fluid to serum sampling, weeks 7.9 5.9
Race/ethnicity
 Non-Hispanic white 16 57.4
 Non-Hispanic black 5 17.9
 Hispanic 4 14.3
 Asian 1 3.6
 American Indian 2 7.1
Education
 High school 7 25.0
 College 10 35.7
 Graduate school 11 39.3
Parity
 0 1 3.9
 1 7 26.9
 2+ 18 69.2
Pre-pregnancy BMI
 Underweight 0 0
 Normal weight 15 53.6
 Overweight 7 25.0
 Obese 6 21.4
Pregnancy weight gain, lbs
0 – 25 7 25.9
26 – 40 10 37.0
41 – 60 10 37.0
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